

# Livio Garattini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6679671/publications.pdf>

Version: 2024-02-01

124  
papers

1,911  
citations

257450

24  
h-index

330143

37  
g-index

127  
all docs

127  
docs citations

127  
times ranked

1627  
citing authors

#	ARTICLE	IF	CITATIONS
1	A comparative analysis of generics markets in five European countries. <i>Health Policy</i> , 2000, 51, 149-162.	3.0	109
2	A Proposal For Italian Guidelines in Pharmacoeconomics. <i>Pharmacoeconomics</i> , 1995, 7, 1-6.	3.3	71
3	The German experience in reference pricing. <i>Health Policy</i> , 1998, 44, 73-85.	3.0	67
4	Current Trends in the Use of Pharmacoeconomics and Outcomes Research in Europe. <i>Value in Health</i> , 1999, 2, 323-332.	0.3	63
5	Budget impact analysis in economic evaluation: a proposal for a clearer definition. <i>European Journal of Health Economics</i> , 2011, 12, 499-502.	2.8	62
6	Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysis. <i>Health Policy</i> , 2007, 82, 330-339.	3.0	59
7	Modeling in pharmacoeconomic studies: Funding sources and outcomes. <i>International Journal of Technology Assessment in Health Care</i> , 2010, 26, 330-333.	0.5	59
8	Italian risk-sharing agreements on drugs: are they worthwhile?. <i>European Journal of Health Economics</i> , 2015, 16, 1-3.	2.8	55
9	Pharmaceutical policy in Italy: towards a structural change?. <i>Health Policy</i> , 2005, 72, 53-63.	3.0	51
10	Prices and distribution margins of in-patent drugs in pharmacy: A comparison in seven European countries. <i>Health Policy</i> , 2008, 85, 305-313.	3.0	50
11	Costs of Diabetes. <i>Pharmacoeconomics</i> , 1999, 15, 583-595.	3.3	48
12	Pain in primary care: an Italian survey. <i>European Journal of Public Health</i> , 2005, 15, 475-479.	0.3	47
13	A Critical Systematic Review of Budget Impact Analyses on Drugs in the EU Countries. <i>Applied Health Economics and Health Policy</i> , 2014, 12, 33-40.	2.1	41
14	More room for telemedicine after COVID-19: lessons for primary care?. <i>European Journal of Health Economics</i> , 2021, 22, 183-186.	2.8	38
15	Regional tenders on biosimilars in Italy: An empirical analysis of awarded prices. <i>Health Policy</i> , 2014, 116, 182-187.	3.0	36
16	Off-patent drugs in Italy. <i>European Journal of Health Economics</i> , 2006, 7, 79-83.	2.8	34
17	Market-access agreements for anti-cancer drugs. <i>Journal of the Royal Society of Medicine</i> , 2015, 108, 166-170.	2.0	33
18	Risk sharing agreements: What lessons from Italy?. <i>International Journal of Technology Assessment in Health Care</i> , 2011, 27, 169-172.	0.5	32

#	ARTICLE	IF	CITATIONS
19	Competition in health markets: is something rotten?. Journal of the Royal Society of Medicine, 2019, 112, 6-10.	2.0	31
20	Defensive medicine in Europe: a "full circle"?. European Journal of Health Economics, 2020, 21, 165-170.	2.8	28
21	Continuing Medical Education in six European countries: A comparative analysis. Health Policy, 2010, 94, 246-254.	3.0	27
22	Cost Effectiveness of the New Pneumococcal Vaccines: A Systematic Review of European Studies. Pharmacoeconomics, 2014, 32, 29-45.	3.3	26
23	Performance-Based Agreements in Italy: "Trendy Outcomes" or Mere Illusions?. Pharmacoeconomics, 2016, 34, 967-969.	3.3	26
24	Pharmaceutical Price Schemes in Europe: Time for a "Continental" One?. Pharmacoeconomics, 2016, 34, 423-426.	3.3	26
25	Improving primary care in Europe beyond COVID-19: from telemedicine to organizational reforms. Internal and Emergency Medicine, 2021, 16, 255-258.	2.0	26
26	Integrative Review of Managed Entry Agreements: Chances and Limitations. Pharmacoeconomics, 2020, 38, 1165-1185.	3.3	25
27	Economic evaluation of human papilloma virus vaccination in the European Union: a critical review. Internal and Emergency Medicine, 2011, 6, 163-174.	2.0	24
28	Durata e costo delle visite in medicina generale: il progetto DYSCO. Farmeconomia E Percorsi Terapeutici, 2003, 4, 109-114.	0.1	24
29	Biosimilar Versus Generic Drugs: Same But Different?. Applied Health Economics and Health Policy, 2015, 13, 125-127.	2.1	23
30	Pricing Human Papillomavirus Vaccines. Pharmacoeconomics, 2012, 30, 213-217.	3.3	22
31	Patient empowerment in Europe: is no further research needed?. European Journal of Health Economics, 2018, 19, 637-640.	2.8	22
32	The Italian NHS: What Lessons to Draw from COVID-19?. Applied Health Economics and Health Policy, 2020, 18, 463-466.	2.1	20
33	Dutch guidelines for economic evaluation: "from good to better" in theory but further away from pharmaceuticals in practice?. Journal of the Royal Society of Medicine, 2017, 110, 98-103.	2.0	19
34	Pharmaceutical care in Italy and other European countries: between care and commerce?. Postgraduate Medicine, 2018, 130, 52-54.	2.0	18
35	Tendering and value-based pricing: lessons from Italy on human papilloma virus vaccines. Journal of the Royal Society of Medicine, 2014, 107, 4-5.	2.0	17
36	Access to primary care in Italy: time for a shake-up?. European Journal of Health Economics, 2016, 17, 113-116.	2.8	16

#	ARTICLE	IF	CITATIONS
37	“Appropriateness”™ in Italy: A “Magic Word”™ in Pharmaceuticals?. Applied Health Economics and Health Policy, 2017, 15, 1-3.	2.1	16
38	Do European pharmacists really have to trespass on medicine?. European Journal of Health Economics, 2021, 22, 1-4.	2.8	16
39	Personalized medicine and economic evaluation in oncology: all theory and no practice?. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 733-738.	1.4	15
40	Pharmaceutical pricing conundrum: time to get rid of it?. European Journal of Health Economics, 2018, 19, 1035-1038.	2.8	15
41	The Italian NHS at regional level: same in theory, different in practice. European Journal of Health Economics, 2022, 23, 1-5.	2.8	15
42	Health technology assessment: for whom the bell tolls?. European Journal of Health Economics, 2008, 9, 311-312.	2.8	14
43	Competition in pharmaceuticals: more product- than price-oriented?. European Journal of Health Economics, 2018, 19, 1-4.	2.8	14
44	Regional HTA in Italy: Promising or confusing?. Health Policy, 2012, 108, 203-206.	3.0	13
45	Cost-effectiveness of trastuzumab in metastatic breast cancer: Mainly a matter of price in the EU?. Health Policy, 2015, 119, 212-216.	3.0	13
46	Dual practice of hospital staff doctors: hippocratic or hypocritic?. Journal of the Royal Society of Medicine, 2018, 111, 265-269.	2.0	13
47	How Do Italian Pharmacoeconomists Evaluate Indirect Costs?. Value in Health, 2000, 3, 270-276.	0.3	12
48	ECONOMIC EVALUATIONS IN ITALY: A REVIEW OF THE LITERATURE. International Journal of Technology Assessment in Health Care, 2003, 19, 685-691.	0.5	12
49	Health status, resource consumption, and costs of dysthymia. A multi-center two-year longitudinal study. Journal of Affective Disorders, 2006, 90, 181-186.	4.1	12
50	A Comparative Analysis of the Pharmaceutical Market in Four European Countries. Pharmacoeconomics, 1994, 6, 417-423.	3.3	11
51	Optional copayments on anti-cancer drugs. BMJ, The, 2013, 346, f349-f349.	6.0	11
52	Market approval for drugs in the EU: time to change direction?. European Journal of Health Economics, 2017, 18, 933-936.	2.8	11
53	English and Italian national health services: Time for more patient-centered primary care?. European Journal of Internal Medicine, 2018, 57, 19-21.	2.2	11
54	Conflict of interest disclosure: striking a balance?. European Journal of Health Economics, 2019, 20, 633-636.	2.8	11

#	ARTICLE	IF	CITATIONS
55	Economic Evaluation of ACE Inhibitor Treatment of Nephropathy in Patients with Insulin-Dependent Diabetes Mellitus in Italy. <i>Pharmacoeconomics</i> , 1997, 12, 67-75.	3.3	10
56	European Medicines Agency: leave the UK but remain the same. <i>Journal of the Royal Society of Medicine</i> , 2016, 109, 324-325.	2.0	10
57	Reimbursable drug classes and ceilings in Italy: why not only one?. <i>European Journal of Health Economics</i> , 2016, 17, 923-926.	2.8	10
58	Defensive medicine in Europe: a "full circle"™?. <i>European Journal of Health Economics</i> , 2020, 21, 477-482.	2.8	10
59	Economic Evaluation of an Educational Campaign for Early Diagnosis of Cutaneous Melanoma. <i>Pharmacoeconomics</i> , 1996, 9, 146-155.	3.3	9
60	HPV Vaccination for Boys? Talking Economic Sense. <i>Journal of Sexual Medicine</i> , 2012, 9, 2195-2196.	0.6	9
61	Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness?. <i>European Journal of Health Economics</i> , 2015, 16, 341-345.	2.8	9
62	Precision medicine and monoclonal antibodies: breach of promise?. <i>Croatian Medical Journal</i> , 2019, 60, 284-289.	0.7	9
63	Will the reform of community pharmacies in Italy be of benefit to patients or the Italian National Health Service?. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 23-26.	0.6	9
64	Will the reform of community pharmacies in Italy be of benefit to patients or the Italian National Health Service?. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 23-26.	0.6	8
65	Between pharmaceutical patents and European patients: is a compromise still possible?. <i>Expert Opinion on Therapeutic Patents</i> , 2017, 27, 1073-1076.	5.0	8
66	Medical Costs of Chronic Musculoskeletal Pain in Italy. <i>Clinical Drug Investigation</i> , 2007, 27, 139-148.	2.2	7
67	The puzzle of drug delivery in Italy: who wins?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 331-332.	1.4	7
68	Cholesterol-lowering drugs: science and marketing. <i>Journal of the Royal Society of Medicine</i> , 2017, 110, 57-64.	2.0	7
69	Clinical Governance in Italy: "Made in England"™ for Import?. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 541-544.	2.1	7
70	Economic Evaluation of Pharmaceuticals. <i>Pharmacoeconomics</i> , 1992, 2, 270-278.	3.3	6
71	Should we really worry about "launch delays" of new drugs in OECD countries?. <i>European Journal of Health Economics</i> , 2007, 8, 1-3.	2.8	6
72	A critical review of the full economic evaluations of pharmacological treatments for colorectal cancer. <i>Journal of Medical Economics</i> , 2008, 11, 177-197.	2.1	6

#	ARTICLE	IF	CITATIONS
73	Management of vaccinations in Italy: a national survey after healthcare regionalization. <i>Journal of Medical Economics</i> , 2011, 14, 527-541.	2.1	6
74	Ethics for end-of-life treatments: Metastatic colorectal cancer is one example. <i>Health Policy</i> , 2013, 109, 97-103.	3.0	6
75	Western European markets for biosimilar and generic drugs: worth differentiating. <i>European Journal of Health Economics</i> , 2015, 16, 683-687.	2.8	6
76	Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?. <i>Pharmacoeconomics</i> , 2015, 33, 1241-1244.	3.3	6
77	Hospital Pharmacists in Europe: Between Warehouse and Prescription Pad?. <i>PharmacoEconomics - Open</i> , 2018, 2, 221-224.	1.8	6
78	Multiple Criteria Decision Analysis in Health Technology Assessment for Drugs: Just Another Illusion?. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 1-4.	2.1	6
79	Conflicts of interest in medicine: a never-ending story. <i>Internal and Emergency Medicine</i> , 2020, 15, 357-359.	2.0	6
80	Integrated care: easy in theory, harder in practice?. <i>Internal and Emergency Medicine</i> , 2022, 17, 3-6.	2.0	6
81	Defensive medicine: Everything and its opposite. <i>European Journal of Internal Medicine</i> , 2020, 74, 117-118.	2.2	6
82	Primary care in a National Health Service: time for radical reform. <i>Family Practice</i> , 2022, 39, 994-995.	1.9	6
83	Cost of schizophrenia studies: a methodological review. <i>European Journal of Health Economics</i> , 2000, 1, 14-19.	0.2	5
84	Influenza vaccine for healthy adult workers: An issue for health authorities or employers?. <i>Health Policy</i> , 2011, 102, 89-95.	3.0	5
85	Could co-payments on drugs help to make EU health care systems less open to political influence?. <i>European Journal of Health Economics</i> , 2013, 14, 709-713.	2.8	5
86	Safety and Quality of Generic Drugs: A Never Ending Debate Fostered by Economic Interests?. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 3-4.	2.1	5
87	Pharmaceutical pricing in Europe: time to take the right direction. <i>Internal and Emergency Medicine</i> , 2022, 17, 945-948.	2.0	5
88	Curing cervical cancer or preventing it: A case of opportunity cost in the long run?. <i>Vaccine</i> , 2014, 32, 6867-6869.	3.8	4
89	Long-term modeling on HPV vaccination: do we really need any more?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 191-194.	1.4	4
90	Do the Current Performance-Based Schemes in Italy Really Work? â€œSuccess Feeâ€: A Novel Measure for Cost-Containment of Drug Expenditure. <i>Value in Health</i> , 2015, 18, 352.	0.3	4

#	ARTICLE	IF	CITATIONS
91	From pharmacy faculty to pharmacy shop: still a logical pathway in Europe?. <i>Drugs and Therapy Perspectives</i> , 2018, 34, 85-88.	0.6	4
92	HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?. <i>European Journal of Health Economics</i> , 2020, 21, 1-5.	2.8	4
93	The dark age of Italian general practice research – An Italian matter. <i>European Journal of Internal Medicine</i> , 2020, 73, 98-99.	2.2	4
94	Vaccination planning and vaccine prices in a decentralizing country – Italy. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 195-202.	1.4	3
95	Why EMA should provide clearer guidance on the authorization of NBCDs in generic and hybrid applications. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1-3.	3.1	3
96	Vaccination planning in Italy: increasing vaccines while reducing coverage?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 547-548.	1.4	3
97	Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?. <i>Pharmacoeconomics</i> , 2016, 34, 221-224.	3.3	3
98	Older anti-TNF- $\alpha$ agents: why not group them for common indications in the EU?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 1-4.	1.4	3
99	Pharmaceutical expenditure control in Europe: time to move from pricing to budgeting?. <i>Journal of the Royal Society of Medicine</i> , 2020, 113, 93-97.	2.0	3
100	Community and hospital pharmacists in Europe: encroaching on medicine?. <i>Internal and Emergency Medicine</i> , 2021, 16, 7-10.	2.0	3
101	A critical review of the full economic evaluations of pharmacological treatments for glaucoma. <i>Journal of Medical Economics</i> , 2008, 11, 719-741.	2.1	2
102	Immunotherapies for advanced melanoma: as promising as they are expensive?. <i>Journal of the Royal Society of Medicine</i> , 2017, 110, 395-399.	2.0	2
103	Pricing of HPV Vaccines in Europe: Back to the Future?. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 275-277.	2.1	2
104	Comment on: –The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study–™. <i>Pharmacoeconomics</i> , 2019, 37, 1301-1302.	3.3	2
105	Health technology assessment for pharmaceutical regulation in the European Union: do we need another body?. <i>Journal of the Royal Society of Medicine</i> , 2020, 113, 12-15.	2.0	2
106	Integrated Care in Europe: Time to Get it Together?. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 145-147.	2.1	2
107	Pharmaceutical patenting in the European Union: reform or riddance. <i>Internal and Emergency Medicine</i> , 2021, , 1.	2.0	2
108	To model or not to model: lessons from two vaccinations. <i>European Journal of Health Economics</i> , 2011, 12, 189-191.	2.8	1

#	ARTICLE	IF	CITATIONS
109	The Bayesian Model on Human Papillomavirus Vaccination in Italy Lacks Transparency. <i>Medical Care</i> , 2013, 51, 374.	2.4	1
110	Comment on: "Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers". <i>Applied Health Economics and Health Policy</i> , 2014, 12, 565-565.	2.1	1
111	Are High Prices a Barrier to Human Papillomavirus Vaccination in the United States? Not in Italy. <i>JAMA Pediatrics</i> , 2014, 168, 584.	6.2	1
112	Comment on: "NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence". <i>Pharmacoeconomics</i> , 2020, 38, 121-122.	3.3	1
113	Comment on: "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition". <i>Applied Health Economics and Health Policy</i> , 2020, 18, 453-454.	2.1	1
114	The Italian NHS in Lombardy and Veneto: near but far. <i>Internal and Emergency Medicine</i> , 2021, 16, 2335-2337.	2.0	1
115	Drug sales in four European countries still differ. <i>BMJ: British Medical Journal</i> , 2003, 327, 1404-c-1405.	2.3	1
116	Should we really worry about "launch delays" of new drugs in OECD countries? Reply to J Cohen. <i>European Journal of Health Economics</i> , 2007, 8, 171-171.	2.8	0
117	Continuing medical education funding and management in Europe: room for improvement?. <i>Journal of Medical Economics</i> , 2009, 12, 56-59.	2.1	0
118	Letter to the Editor. <i>Vaccine</i> , 2011, 29, 2229-2229.	3.8	0
119	The Authors' Reply. <i>Pharmacoeconomics</i> , 2012, 30, 443-445.	3.3	0
120	Urgent reforms for general practice in Italy. <i>European Journal of Internal Medicine</i> , 2019, 64, e17.	2.2	0
121	Pricing vaccines and drugs in Europe: worth differentiating?. <i>European Journal of Health Economics</i> , 2021, 22, 1345-1348.	2.8	0
122	Pharmaceutical Patents in Europe: Radical Reforms Rather Than Getting Rid?. <i>Applied Health Economics and Health Policy</i> , 2021, , 1.	2.1	0
123	Community care reform in Italy: Get a move on!. <i>European Journal of Internal Medicine</i> , 2022, , .	2.2	0
124	Integrated care in Western Europe: a wise solution for the future?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, , 1-5.	1.4	0